Dr. ASHISH SHARMA (S13838)

Abstract

Intraocular inflammation with initial use of Razumab, the biosimilar to ranibizumab brought immunogenicity of biologics in focus. It created a nocebo effect around the use of biosimilars, which persisted even after biosimilar to have shown a near-zero IOI rate. Biosimilars and the longer acting drugs such as brolucizumab and abicipar pegol are the future of intravitreal therapy to lessen the financial burden. The recent incidences of occlusive vasculitis occurring in 21 cases of brolucizumab, which led FDA to issue to vigilance alert, and incidence of sterile inflammation with abicipar warrants a better understanding of such IOI. The course aims to provide a general overview of the causes of such immunogenic reactions, mechanisms for each factor involved in the immunogenicity, and the steps required to mitigate the risks in form of didactic lectures. The course dedicates time for panel discussion and audience interaction for a better understanding of the subject.

1	Introduction to the course (5 mins)	Dr. ASHISH SHARMA	watch video
2	Understanding immunogenicity in the eye (10 mins)	Dr. Nilesh Kumar	watch video
3	Immunogenic reaction: How to differentiate from other inflammation (10 mins)	Dr.Narayanan R	watch video
4	Understanding the sources of immunogenicity: Drugs and Injection Technique (10 mins)	Dr. ASHISH SHARMA	watch video
5	Lessons learnt from biosimilars (10 mins)	Dr. S.NATARAJAN	watch video
6	Brolucizumab and Occlusive Vasculitis: Understanding the new phenomenon (10 mins)	Dr. ASHISH SHARMA	watch video
	Panel Discussion : (20 mins.)